Eli Lilly (LLY) news

Older LLY news events, each with the realized, point-in-time move the market made — page 3 of 8. Back to the LLY overview → · Full LLY reaction history →

Latest news

Recent LLY events, each with its measured reaction. (Page 3 of 8.)

DateHeadlineEventSource5-minTo close
Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facilityPress releasePR Newswire+0.25%+0.95%
Jaypirca® (pirtobrutinib), the First and Only Non-Covalent (Reversible) BTK Inhibitor, Now Available in Canada for Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma and Chronic Lymphocytic LeukemiaPress releaseCanada Newswire+0.67%-2.31%
Lilly confirms date and conference call for fourth-quarter 2025 financial results announcementPress releasePR Newswire+0.20%+1.00%
Lilly's sofetabart mipitecan receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancerPress releasePR Newswire+1.42%+2.09%
Ontario Pioneers Access to Treatment for Severe Alopecia Areata with Lilly's Olumiant®Press releaseCanada Newswire-0.51%-0.78%
Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public MarketsPress releaseBusiness Wire-0.14%-1.63%
Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweightPress releasePR Newswire+0.27%+0.07%
Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseasesPress releasePR Newswire+1.15%-2.56%
Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trialPress releasePR Newswire+2.41%+1.45%
Lilly to participate in J.P. Morgan Healthcare ConferencePress releasePR Newswire+0.53%+0.03%
Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancerPress releasePR Newswire-0.00%+1.04%
Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trialPress releasePR Newswire-1.01%-0.36%
Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisitionPress releasePR Newswire+0.35%-2.12%
Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in AlabamaPress releasePR Newswire-0.22%-0.55%
Lilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with treatment-naïve CLL/SLLPress releasePR Newswire+0.35%-2.12%
Carolyn Bertozzi returns to Lilly board of directorsPress releasePR Newswire-0.20%-0.10%
Lilly declares first-quarter 2026 dividendPress releasePR Newswire+0.16%+0.39%
Lilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib)Press releasePR Newswire-0.86%-1.30%
U.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitorPress releasePR Newswire-0.15%-0.32%
Lilly to highlight progress across key programs in early and advanced hormone receptor-positive breast cancer at the 2025 San Antonio Breast Cancer SymposiumPress releasePR Newswire+1.08%+3.37%
Lilly to present data from two positive Phase 3 studies of Jaypirca (pirtobrutinib) in chronic lymphocytic leukemia at the 2025 American Society of Hematology (ASH) Annual MeetingPress releasePR Newswire+0.01%+0.39%
Form 8-K ELI LILLY & Co For: Nov 18SEC filing · Form 8-KSEC EDGAR+0.52%+0.90%
Lilly announces plans to open Lilly Gateway Labs site in PhiladelphiaPress releasePR Newswire+0.77%+1.89%
Lilly to participate in Citi's 2025 Global Healthcare ConferencePress releasePR Newswire+0.00%+0.60%
Queer Eye's Tan France helps unthread obesity bias as part of Zepbound's (tirzepatide) 'Changing the Thread Collection'Press releasePR Newswire+1.04%+1.86%
Lilly and U.S. government agree to expand access to obesity medicines to millions of AmericansPress releasePR Newswire+0.36%+1.51%
Lilly announces two new Executive Committee members and expansion of leadership roles to prepare for next wave of growthPress releasePR Newswire-0.73%-0.73%
Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweightPress releasePR Newswire+0.40%+1.02%
Lilly plans to build a new $3 billion facility to boost oral medicine manufacturing capacity in Europe for patients worldwidePress releasePR Newswire+1.70%+3.47%
Lilly plans to build a new €2.6 billion facility to boost oral medicine manufacturing capacity in Europe for patients worldwidePress releasePR Newswire+0.05%+1.43%
Form 10-Q ELI LILLY & Co For: Sep 30SEC filing · Form 10-QSEC EDGAR+0.45%+0.00%
Form 8-K ELI LILLY & Co For: Oct 30SEC filing · Form 8-KSEC EDGAR-1.72%+0.66%
Lilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidancePress releasePR Newswire-1.72%+0.66%
Lilly announces more than $1.2 billion investment in Puerto Rico facility to boost oral medicine manufacturing capacity in the United StatesPress releasePR Newswire-0.14%-1.01%
LillyDirect and Walmart Pharmacy launch first retail pick-up option with direct-to-consumer pricing for ZepboundPress releasePR Newswire-1.01%-1.63%
Lilly announces roster of Team USA athletes for the Olympic and Paralympic Games Milano Cortina 2026, pledges to translate U.S. Olympic and Paralympic milestones into meaningful community impactPress releasePR Newswire+0.17%+0.09%
Lilly partners with NVIDIA to build the industry's most powerful AI supercomputer, supercharging medicine discovery and delivery for patientsPress releasePR Newswire+0.49%+0.31%
Lilly declares fourth-quarter 2025 dividendPress releasePR Newswire+0.11%+0.49%
Lilly Drafts Shaquille O'Neal to Raise Awareness for Moderate-to-Severe Obstructive Sleep ApneaPress releasePR Newswire+0.09%+0.65%
Lilly's Omvoh (mirikizumab-mrkz) approved by U.S. FDA as a single-injection maintenance regimen in adults with ulcerative colitisPress releasePR Newswire-0.33%-0.71%
Lilly's Omvoh (mirikizumab-mrkz) demonstrated early and sustained improvement in bowel urgency outcomes for patients with ulcerative colitisPress releasePR Newswire-0.75%+0.17%
Lilly to Acquire Adverum BiotechnologiesPress releasePR Newswire+0.33%+1.26%
Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trialPress releasePR Newswire+0.33%+1.26%
Lilly's EBGLYSS (lebrikizumab-lbkz) delivered durable disease control when administered once every eight weeks in patients with moderate-to-severe atopic dermatitisPress releasePR Newswire+0.33%+1.26%
Lilly's Verzenio® (abemaciclib) prolonged survival in HR+, HER2-, high-risk early breast cancer with two years of treatmentPress releasePR Newswire+1.35%+1.96%
Lilly confirms date and conference call for third-quarter 2025 financial results announcementPress releasePR Newswire+0.05%-1.69%
Lilly's oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetesPress releasePR Newswire-0.05%+1.75%
Lilly to present new clinical data for Verzenio (abemaciclib) and multiple novel pipeline programs at the 2025 European Society for Medical Oncology (ESMO) Annual MeetingPress releasePR Newswire-0.10%-1.59%
Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitisPress releasePR Newswire-0.41%-0.16%
Lilly opens newest Gateway Labs site in San Diego to boost local biotechnology ecosystemPress releasePR Newswire-0.27%+0.06%

Each headline opens its own page with the full realized reaction — the move the market actually made, measured from the news timestamp.

Stop guessing what the event means.

claude mcp add news-quantified
Get free API keyTry the playground